iifl-logo-icon 1
IIFL

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Lupin Hits 52-Week High as FDA Greenlights Febuxostat Tablets for Gout Treatment in the U.S.

19 Jan 2024 , 10:57 AM

Lupin Ltd's shares hit a fresh 52-week high after obtaining approval from the U.S. FDA for Febuxostat Tablets on January 18. The approval allows Lupin to market a generic equivalent of Uloric® Tablets by Takeda Pharmaceuticals U.S.A.

Febuxostat Tablets, with indications for managing hyperuricemia in adult gout patients, will be manufactured at Lupin's Pithampur facility in India.

Lupin's current market price on BSE stands at Rs 1430.00 per share, reflecting an intraday gain of 0.33%. The stock previously hit a 52-week high on January 18, accompanied by a notable surge in trading volume (more than 2.17 times). Lupin's market capitalization is Rs 65,293.83 crore.

According to Lupin's press release dated January 18, 2024, Febuxostat Tablets (40 mg and 80 mg) are designed for adult gout patients with an inadequate response to allopurinol or intolerance to it.

The estimated annual sales of Febuxostat Tablets (RLD Uloric®) in the U.S. were USD 27 million as of IQVIA MAT November 2023.

Lupin, headquartered in Mumbai, India, is an innovation-led pharmaceutical company operating globally. The company focuses on developing and commercializing branded and generic formulations, biotechnology products, and APIs in various markets worldwide, including the U.S., India, South Africa, Asia Pacific, Latin America, Europe, and the Middle East.

For feedback and suggestions, write to us at editorial@iifl.com

Related Tags

  • 52-week high
  • business
  • Company
  • Febuxostat Tablets
  • Lupin
  • news
  • Top gainers
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Most Read News

Awfis IPO oversubscribed 4.19x on day two
23 May 2024|09:51 PM
Indian markets end the day on high
23 May 2024|03:59 PM
Markets surge

Markets surge

Whatsapp
Facebook
Twitter
LinkedIn
23 May 2024|03:45 PM
MG Motor India to supply 3000 EVs to Vertelo
23 May 2024|03:46 PM
Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.